HRP20191491T1 - Biotin za liječenje demijelinizirajućih neuropatija - Google Patents
Biotin za liječenje demijelinizirajućih neuropatija Download PDFInfo
- Publication number
- HRP20191491T1 HRP20191491T1 HRP20191491T HRP20191491T1 HR P20191491 T1 HRP20191491 T1 HR P20191491T1 HR P20191491 T HRP20191491 T HR P20191491T HR P20191491 T1 HRP20191491 T1 HR P20191491T1
- Authority
- HR
- Croatia
- Prior art keywords
- biotin
- use according
- patient
- treatment
- daily amount
- Prior art date
Links
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 title claims 58
- 229960002685 biotin Drugs 0.000 title claims 29
- 235000020958 biotin Nutrition 0.000 title claims 29
- 239000011616 biotin Substances 0.000 title claims 29
- 230000003210 demyelinating effect Effects 0.000 title claims 4
- 201000001119 neuropathy Diseases 0.000 title claims 4
- 230000007823 neuropathy Effects 0.000 title claims 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 claims 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 2
- 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 claims 2
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010060880 Monoclonal gammopathy Diseases 0.000 claims 1
- 208000002774 Paraproteinemias Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 235000010603 pastilles Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Magnetic Ceramics (AREA)
- Farming Of Fish And Shellfish (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Manufacture, Treatment Of Glass Fibers (AREA)
Claims (17)
1. Biotin za njegovu upotrebu u liječenju demijelinizirajuće neuropatije, naznačen time što je navedena demijelinizirajuća neuropatija odabrana iz skupine koja se sastoji od demijelinizirajuće neuropatije povezane s imunoglobulinskom M (IgM) monoklonskom gamopatijom i protutijelima protiv glikoproteina povezanog s mijelinom (MAG), tipične kronične upalne demijelinizirajuće poliradikuloneuropatije, atipične kronične upalne demijelinizirajuće poliradikuloneuropatije, Charcot-Marie-Toothova bolest Ia i Guillain-Barreov sindrom.
2. Biotin za uporabu prema patentnom zahtjevu 1, naznačen time što dnevna količina biotina koja se daje pacijentu iznosi između 50 i 700 mg.
3. Biotin za uporabu prema patentnom zahtjevu 1 ili 2, naznačen time što dnevna količina biotina koja se daje pacijentu iznosi najmanje 100 mg.
4. Biotin za uporabu prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time što dnevna količina biotina koja se daje pacijentu iznosi najmanje 150 mg.
5. Biotin za uporabu prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time što dnevna količina biotina koja se daje pacijentu iznosi između 100 mg i 300 mg.
6. Biotin za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time što je u obliku pripravka prikladnog za oralnu primjenu.
7. Biotin za uporabu prema patentnom zahtjevu 6, naznačen time što jedinična doza pripravka sadrži najmanje 20 mg biotina.
8. Biotin za uporabu prema patentnom zahtjevu 6 ili 7, naznačen time što jedinična doza pripravka sadrži najmanje 50 mg biotina.
9. Biotin za uporabu prema bilo kojem od patentnih zahtjeva 6 do 7, naznačen time što jedinična doza pripravka sadrži 100 mg biotina.
10. Biotin za uporabu prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time što je u obliku gel kapsula, tableta (po izboru obloženih filmom), pastila ili pilula.
11. Biotin za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time što je u obliku pripravka koji sadrži biotin i pomoćne tvari, bez bilo kojeg drugog aktivnog sastojka.
12. Biotin za uporabu prema patentnom zahtjevu 11, naznačen time što su pomoćne tvari izabrane iz skupine koja se sastoji od talka, mikrokristalne celuloze, laktoze i manoze.
13. Biotin za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time što je oblik pogodan za injektiranje.
14. Biotin za uporabu prema bilo kojem od patentnih zahtjeva 1 do 13, naznačen time što je u obliku pripravka sa sporim otpuštanjem.
15. Biotin za uporabu prema bilo kojem od patentnih zahtjeva 1 do 14, naznačen time što navedeno liječenje s biotinom traje najmanje 3 mjeseca.
16. Biotin za uporabu prema bilo kojem od patentnih zahtjeva 1 do 15, naznačen time što navedeno liječenje s biotinom traje najmanje 6 mjeseci.
17. Biotin za uporabu prema bilo kojem od patentnih zahtjeva 1 do 16, naznačen time što navedeno liječenje s biotinom traje najmanje godinu dana.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305437.4A EP3072513A1 (en) | 2015-03-26 | 2015-03-26 | Biotin for treating Amyotrophic lateral sclerosis |
| EP16713833.8A EP3273957B1 (en) | 2015-03-26 | 2016-03-25 | Biotin for treating demyelinating neuropathies |
| PCT/EP2016/056696 WO2016151132A1 (en) | 2015-03-26 | 2016-03-25 | Biotin for treating amyotrophic lateral sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191491T1 true HRP20191491T1 (hr) | 2019-11-15 |
Family
ID=52779582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191491 HRP20191491T1 (hr) | 2015-03-26 | 2019-08-19 | Biotin za liječenje demijelinizirajućih neuropatija |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10357480B2 (hr) |
| EP (2) | EP3072513A1 (hr) |
| JP (1) | JP6752874B2 (hr) |
| KR (1) | KR20170131543A (hr) |
| CN (2) | CN107405335A (hr) |
| AU (1) | AU2016238759B2 (hr) |
| BR (1) | BR112017020408A2 (hr) |
| CA (1) | CA2980660A1 (hr) |
| CY (1) | CY1122374T1 (hr) |
| DK (1) | DK3273957T3 (hr) |
| EA (1) | EA034394B1 (hr) |
| ES (1) | ES2748354T3 (hr) |
| HR (1) | HRP20191491T1 (hr) |
| HU (1) | HUE046116T2 (hr) |
| IL (1) | IL254619B (hr) |
| LT (1) | LT3273957T (hr) |
| MA (1) | MA41809B1 (hr) |
| ME (1) | ME03567B (hr) |
| PL (1) | PL3273957T3 (hr) |
| PT (1) | PT3273957T (hr) |
| RS (1) | RS59149B1 (hr) |
| SI (1) | SI3273957T1 (hr) |
| WO (1) | WO2016151132A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3072513A1 (en) | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
| EP3275439A1 (en) | 2016-07-29 | 2018-01-31 | Medday Pharmaceuticals | Method for treating hepatic encephalopathy |
| CN112386703A (zh) * | 2020-01-15 | 2021-02-23 | 李启芳 | 治疗als的联合用药物及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5885976A (en) * | 1995-05-08 | 1999-03-23 | Sandyk; Reuven | Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions |
| RS20050255A (en) | 2002-09-27 | 2007-08-03 | Biogen Idec Ma Inc., | Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-betha |
| US20050249823A1 (en) * | 2003-11-04 | 2005-11-10 | Murphy Tanya K | Methods for the prevention or amelioration of neuropsychiatric and related diseases |
| US7105183B2 (en) * | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
| FR2905868B1 (fr) * | 2006-09-18 | 2012-12-21 | Gemac | Composition destinee au traitement de la sclerose laterale amyotrophique |
| US20130004545A1 (en) | 2009-12-23 | 2013-01-03 | Lupin Limited | Slow release pharmaceutical compositions of iloperidone |
| FR2958166B1 (fr) | 2010-04-06 | 2012-07-13 | Assist Publ Hopitaux De Paris | Compositions pharmaceutiques fortement dosees en biotine |
| FR2993780B1 (fr) * | 2012-07-26 | 2015-02-13 | Assist Publ Hopitaux De Paris | Methode de traitement de la sclerose en plaque |
| WO2012145746A1 (en) * | 2011-04-21 | 2012-10-26 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for the treatment of neuromyelitis optica |
| CN109316480A (zh) * | 2011-07-13 | 2019-02-12 | 赛特凯恩蒂克公司 | 组合als疗法 |
| WO2014177286A1 (en) | 2013-04-29 | 2014-11-06 | Assistance Publique - Hopitaux De Paris | Biotin for use in treating x-linked adrenoleukodystrophy |
| JP6664956B2 (ja) * | 2015-02-27 | 2020-03-13 | キリンホールディングス株式会社 | 筋分化促進組成物 |
| EP3072513A1 (en) | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
-
2015
- 2015-03-26 EP EP15305437.4A patent/EP3072513A1/en not_active Ceased
-
2016
- 2016-03-25 WO PCT/EP2016/056696 patent/WO2016151132A1/en active Application Filing
- 2016-03-25 RS RS20191089A patent/RS59149B1/sr unknown
- 2016-03-25 CN CN201680018463.8A patent/CN107405335A/zh active Pending
- 2016-03-25 HU HUE16713833A patent/HUE046116T2/hu unknown
- 2016-03-25 SI SI201630372T patent/SI3273957T1/sl unknown
- 2016-03-25 EA EA201792124A patent/EA034394B1/ru not_active IP Right Cessation
- 2016-03-25 US US15/561,911 patent/US10357480B2/en not_active Expired - Fee Related
- 2016-03-25 CA CA2980660A patent/CA2980660A1/en not_active Abandoned
- 2016-03-25 PT PT16713833T patent/PT3273957T/pt unknown
- 2016-03-25 JP JP2018500860A patent/JP6752874B2/ja not_active Expired - Fee Related
- 2016-03-25 DK DK16713833T patent/DK3273957T3/da active
- 2016-03-25 ME MEP-2019-285A patent/ME03567B/me unknown
- 2016-03-25 AU AU2016238759A patent/AU2016238759B2/en not_active Ceased
- 2016-03-25 ES ES16713833T patent/ES2748354T3/es active Active
- 2016-03-25 KR KR1020177030427A patent/KR20170131543A/ko unknown
- 2016-03-25 LT LT16713833T patent/LT3273957T/lt unknown
- 2016-03-25 BR BR112017020408A patent/BR112017020408A2/pt not_active Application Discontinuation
- 2016-03-25 CN CN202010704334.2A patent/CN111973592A/zh active Pending
- 2016-03-25 MA MA41809A patent/MA41809B1/fr unknown
- 2016-03-25 EP EP16713833.8A patent/EP3273957B1/en active Active
- 2016-03-25 PL PL16713833T patent/PL3273957T3/pl unknown
-
2017
- 2017-09-24 IL IL254619A patent/IL254619B/en active IP Right Grant
-
2019
- 2019-06-25 US US16/451,654 patent/US20190314342A1/en not_active Abandoned
- 2019-08-19 HR HRP20191491 patent/HRP20191491T1/hr unknown
- 2019-11-13 CY CY20191101195T patent/CY1122374T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016238759B2 (en) | 2020-08-06 |
| JP6752874B2 (ja) | 2020-09-09 |
| PT3273957T (pt) | 2019-09-18 |
| EA034394B1 (ru) | 2020-02-04 |
| EA201792124A1 (ru) | 2018-04-30 |
| CY1122374T1 (el) | 2021-01-27 |
| KR20170131543A (ko) | 2017-11-29 |
| JP2018512451A (ja) | 2018-05-17 |
| US20180125825A1 (en) | 2018-05-10 |
| PL3273957T3 (pl) | 2020-01-31 |
| RS59149B1 (sr) | 2019-09-30 |
| HUE046116T2 (hu) | 2020-02-28 |
| SI3273957T1 (sl) | 2019-11-29 |
| EP3072513A1 (en) | 2016-09-28 |
| ME03567B (me) | 2020-07-20 |
| EP3273957A1 (en) | 2018-01-31 |
| DK3273957T3 (da) | 2019-11-11 |
| US20190314342A1 (en) | 2019-10-17 |
| AU2016238759A1 (en) | 2017-10-05 |
| LT3273957T (lt) | 2019-11-11 |
| CN111973592A (zh) | 2020-11-24 |
| WO2016151132A1 (en) | 2016-09-29 |
| EP3273957B1 (en) | 2019-08-14 |
| NZ735528A (en) | 2021-09-24 |
| IL254619A0 (en) | 2017-11-30 |
| BR112017020408A2 (pt) | 2018-06-05 |
| US10357480B2 (en) | 2019-07-23 |
| CA2980660A1 (en) | 2016-09-29 |
| IL254619B (en) | 2020-03-31 |
| CN107405335A (zh) | 2017-11-28 |
| MA41809B1 (fr) | 2019-12-31 |
| ES2748354T3 (es) | 2020-03-16 |
| MA41809A (fr) | 2018-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191491T1 (hr) | Biotin za liječenje demijelinizirajućih neuropatija | |
| JP2015038135A5 (hr) | ||
| JP2017149726A5 (hr) | ||
| JP2014111603A5 (hr) | ||
| HRP20150260T1 (hr) | Uporaba biotina za lijeäśenje multiple skleroze | |
| JP2012193216A5 (hr) | ||
| JP2013155188A5 (hr) | ||
| JP2015083580A5 (hr) | ||
| JP2016147915A5 (hr) | ||
| BR112018012870A2 (pt) | métodos e composições para o tratamento de transtornos relacionados à crise | |
| NZ737561A (en) | Oral composition of celecoxib for treatment of pain | |
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| JP2019530706A5 (hr) | ||
| JP2018522028A5 (hr) | ||
| MX2020012377A (es) | Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades. | |
| MX2018000084A (es) | Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina. | |
| PH12021550218A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| JP2018530578A5 (hr) | ||
| JP2016505050A5 (hr) | ||
| HRP20191798T1 (hr) | Postupak liječenja jetrene encefalopatije | |
| JP2018512451A5 (hr) | ||
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| JP2019522030A5 (hr) | ||
| JP2017530142A5 (hr) | ||
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. |